Chronos Therapeutics, a private biotech company focused on ageing diseases, brain and nervous system disorders, announced that Dr. Huw Jones, CEO of Chronos, has been awarded Best CEO in the European Drug Discovery Industry by online and print magazine European CEO.
Dr. Jones was one of six finalists nominated anonymously for this prestigious award in 2016. The award follows a transformative year for Chronos with several key patents submitted, important preclinical data developing for the company’s lead asset as well as the first acquisition which was concluded in July 2016. The innovative transaction saw Chronos acquiring global rights to three new chemical entity preclinical programs targeting the central nervous system from a subsidiary of Shire with the seller becoming a shareholder in the business in return.
Dr. Huw Jones, CEO of Chronos Therapeutics, said, “This award recognizes Chronos’ team effort in developing and acquiring treatments for patients with degenerative and behavioral diseases. We are developing a re-purposed asset for the devastating disease ALS and actively searching for more discoveries in neurodegeneration. We recently concluded an innovative deal with Shire that adds value to Chronos and has the potential to alleviate significant suffering.”